XNAS
SWKHL
Market cap192mUSD
Oct 08, Last price
25.07USD
1D
0.02%
1Q
-0.89%
Name
SWK Holdings Corp
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Key people
Winston L. Black
Chairman of the Board, Chief Financial Officer · since 2019
Charles M. Jacobson
Chief Financial Officer · since 2012
D. Blair Baker
Independent Director · since 2014
Aaron G.L. Fletcher
Independent Director · since 2019
Independent Director · since 2014
Edward B. Stead
Independent Director · since 2014
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||